These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27621624)

  • 21. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
    Nafee N; Gouda N
    Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.
    DeMarino C; Schwab A; Pleet M; Mathiesen A; Friedman J; El-Hage N; Kashanchi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):31-50. PubMed ID: 27372507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards nanomedicines for neuroAIDS.
    Sagar V; Pilakka-Kanthikeel S; Pottathil R; Saxena SK; Nair M
    Rev Med Virol; 2014 Mar; 24(2):103-24. PubMed ID: 24395761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain.
    Wong HL; Chattopadhyay N; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):503-17. PubMed ID: 19914319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.
    Mohapatra P; Gopikrishnan M; Doss C GP; Chandrasekaran N
    Int J Nanomedicine; 2024; 19():2441-2467. PubMed ID: 38482521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.
    Edagwa BJ; Zhou T; McMillan JM; Liu XM; Gendelman HE
    Curr Med Chem; 2014; 21(36):4186-98. PubMed ID: 25174930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood-brain barrier and neuro-AIDS.
    Zhang YL; Ouyang YB; Liu LG; Chen DX
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4927-39. PubMed ID: 26744885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery.
    Saxena SK; Tiwari S; Nair MP
    Nanomedicine (Lond); 2012 Jul; 7(7):941-4. PubMed ID: 22846087
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
    Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
    J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
    Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
    Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NanoART, neuroAIDS and CNS drug delivery.
    Nowacek A; Gendelman HE
    Nanomedicine (Lond); 2009 Jul; 4(5):557-74. PubMed ID: 19572821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smart branched polymer drug conjugates as nano-sized drug delivery systems.
    Duro-Castano A; Movellan J; Vicent MJ
    Biomater Sci; 2015 Oct; 3(10):1321-34. PubMed ID: 26266272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanomedicines for treatment of viral diseases.
    Mehendale R; Joshi M; Patravale VB
    Crit Rev Ther Drug Carrier Syst; 2013; 30(1):1-49. PubMed ID: 23510109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.
    Date AA; Destache CJ
    Biomaterials; 2013 Aug; 34(26):6202-28. PubMed ID: 23726227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary.
    Skanji R; Andrieux K; Lalanne M; Caron J; Bourgaux C; Degrouard J; Brisset F; Gueutin C; Chacun H; Dereuddre-Bosquet N; Paci A; Vassal G; Bauduin L; Garcia-Argote S; Rousseau B; Clayette P; Desmaële D; Couvreur P
    Int J Pharm; 2011 Jul; 414(1-2):285-97. PubMed ID: 21596125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
    Gupta U; Jain NK
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):478-90. PubMed ID: 19913579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.